Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel and XPartners in connection with the acquisition of NXTLEV
Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of NXTLEV

February 14, 2024 M&A Real Estate and Construction

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of NXTLEV Holding AB and its subsidiaries (”NXTLEV”).

NXTLEV specialises in the building and construction industry and offers qualified services within project management, design management, construction management, etc. NXTLEV is involved in several major projects including, among others, the capacity increase of Saltsjöbanan, Spårväg Syd, Förbifart Stockholm, Södertälje Sluss and Kanal.

Vinge's team consisted of partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Gustav Persson, Egil Svensson, Sara Passandideh, Filip Magnusson and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025